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Kimber L. Stanhopeb, Rosemarie Plaetkea, Gerald V. Mohatta, Bert B. Boyera
aCenter for Alaska Native Health Research, Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, AK 99775-7000, USA
bDepartment of Molecular Biosciences, School of Veterinary Medicine, and Department of Nutrition, University of California Davis, Davis, CA 95616, USAAbstract
Adiponectin, a protein secreted by adipose tissue, has antiatherogenic, anti-inflammatory, and insulin-sensitizing actions. We examined
the relationship between plasma adiponectin and adiposity, insulin resistance, plasma lipids, glucose, leptin, and anthropometric
measurements in 316 adult men and 353 adult women Yup'ik Eskimos in Southwest Alaska. Adiponectin concentration was negatively
associated with body mass index, percentage of body fat, sum of skin folds, waist circumference, triglycerides, insulin resistance
(homeostasis model assessment of insulin resistance [HOMA-IR]), fasting insulin, and leptin in both men and women, and also with glucose
in women. Adiponectin concentration correlated positively with high-density lipoprotein cholesterol concentration, and also with low-density
lipoprotein cholesterol in women. Insulin-sensitive individuals (HOMA-IR b3.52, n = 442) had higher plasma adiponectin concentrations
than more insulin-resistant individuals (HOMA-IR ≥3.52, n = 224): 11.02 ± 0.27 μg/mL vs 8.26 ± 0.32 μg/mL, P b .001. Adiponectin
concentrations did not differ between groups of participants with low and high level of risk for developing coronary heart disease. No
difference in plasma adiponectin levels was found among Yup'ik Eskimos and whites matched for sex, age, and body mass index. In
conclusion, circulating adiponectin concentrations were most strongly associated with sum of skin folds in Yup'ik men and with high-density
lipoprotein cholesterol levels, sum of skin folds, waist circumference, and insulin and triglycerides concentrations in Yup'ik women.
© 2009 Elsevier Inc. All rights reserved.1. Introduction
Obesity is a risk factor for the development of type 2
diabetes mellitus, hypertension, hyperlipidemia, and cardio-
vascular disease [1]. Adipose tissue is an endocrine organ
that secretes a number of hormones and metabolites that
participate in the regulation of insulin sensitivity and
energy metabolism [2,3].
Adiponectin is a 244–amino acid protein that is secreted
specifically by adipose tissue [4]. This collagen-likeThis research has been previously published in abstract form at the 2005
North American Association for the Study of Obesity annual meeting in
Vancouver, British Columbia, Canada.
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doi:10.1016/j.metabol.2008.09.002cytokine has antiatherogenic [5], anti-inflammatory [6],
and insulin-sensitizing actions [3]. Unlike most hormones
produced by adipose tissue, circulating concentrations of
adiponectin are decreased in obese animals and humans
[3,7]; and low levels of adiponectin are predictive of the
development of both cardiovascular disease [8-11] and type
2 diabetes mellitus [12].
Results of several studies suggest that increased
intraabdominal fat contributes to reduced circulating
adiponectin levels [13-16]. Individuals with coronary artery
disease and/or type 2 diabetes mellitus also have lower
plasma adiponectin levels than age- and body mass index
(BMI)–matched nondiabetic individuals without coronary
artery disease [5,17]. However, in Pima Indians with type 2
diabetes mellitus of duration of more than 10 years, serum
adiponectin concentrations were higher than in those with
impaired glucose regulation or diabetes of less than
10 years [18]. Plasma adiponectin levels, as well as the
relationships between adiponectin and anthropometric
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[12,19-22]. In addition, ethnic differences in the predictive
value of circulating adiponectin concentrations and coro-
nary heart disease (CHD) have been reported [23]. Studies
in populations with different body fat distribution patterns
are needed to obtain further understanding of the role of
adiponectin in metabolic diseases in humans. Moreover,
population groups with unusually high or low prevalence of
type 2 diabetes mellitus or CHD might be especially useful
in investigating the role of adiponectin in the pathogenesis
of obesity and comorbidities.
In the present study, we examined the relationship
between plasma adiponectin concentration and BMI,
percentage of body fat (%BF), body fat distribution, insulin
resistance, and plasma lipids in Yup'ik Eskimos from
Southwest Alaska. The prevalence of obesity in Yup'ik
men is similar to that seen in men in the National Health and
Nutrition Examination Survey (NHANES) III cohort, and
Yup'ik women show higher prevalence of obesity than
women in the NHANES (unpublished); but Yup'ik Eskimos
currently have a relatively low prevalence of cardiovascular
disease [24] and type 2 diabetes mellitus [25]. They also
have relatively low levels of plasma triglycerides and
elevated high-density lipoprotein cholesterol (HDL-C) levels
(unpublished). The aims of this study were to evaluate
associations between adiponectin and BMI, %BF, anthropo-
metric measurements, insulin resistance, and plasma lipids in
Yup'ik Eskimos and to compare adiponectin levels in
individuals with normal (NFG) and impaired fasting glucose
(IFG) to determine potential relationships between plasma
adiponectin levels and protection from type 2 diabetes
mellitus and cardiovascular disease in this study population.2. Participants and methods
2.1. Participants
The participants are from the Center for Alaska Native
Health Research (CANHR) study [26] consisting of Yup'ik
Eskimos residing in several rural communities in the
Yukon-Kuskokwim Delta region of Southwest Alaska. The
participants were recruited from December 2003 through
March 2007. In this analysis, nonpregnant Yup'ik Eskimo
participants 18 years or older were included. There were
669 adult Yup'ik Eskimos (316 men and 353 women)
aged 18 to 94 years who met the inclusion criteria. The
CANHR study is approved by the Institutional Review
Board (IRB) at the University of Alaska Fairbanks, the
Alaska Area IRB, the National Indian Health Service IRB,
and the Yukon-Kuskokwim Health Corporation Human
Studies Committee.
2.2. Blood parameters
All blood samples were drawn after at least an 8-hour fast,
samples were centrifuged, and plasma was stored at −15°C
in the field and then transferred to −80°C within 2 weeks.Adiponectin was assayed with a radioimmunoassay kit using
an I215-iodinated murine adiponectin tracer, multispecies
adiponectin rabbit antiserum, and human adiponectin
standards from Linco Research (St Charles, MO). The
intra- and interassay coefficients of variation were 7.1% and
12.1%, respectively. Insulin and leptin were assayed with
radioimmunoassay kits from Linco Research. Intra- and
interassay coefficients of variation were 5.8% and 10.4%,
respectively, for insulin assays and 6.7% and 11.1%,
respectively, for leptin assays.
High-density lipoprotein cholesterol, low-density lipopro-
tein cholesterol (LDL-C), and triglycerides were measured
with a Poly-Chem System Chemistry Analyzer (Polymedco,
Cortlandt Manor, NY). Laboratory intra- and interassay
coefficients of variation were 3.6% and 3.9%, respectively,
for HDL-C and 3.2% and 4.1%, respectively, for triglycerides.
Plasma glucose concentrations were measured using a
lipid and glucose analyzer (LDX; Cholestech, Hayward,
CA). We used the diagnostic and classification criteria
issued by the American Diabetes Association (Clinical
Practice Recommendations 2004) to interpret the values of
fasting plasma glucose: NFG was considered to be less than
100 mg/dL, IFG was considered to be at least 100 mg/dL
and less than 126 mg/dL, and fasting blood glucose of at
least 126 mg/dL met the threshold for the diagnosis of type
2 diabetes mellitus. Clinically diagnosed diabetic patients
or individuals on glucose- or lipid-lowering medications
were not included in this analysis.
The estimate of insulin resistance by the homeostatic
model assessment ratio (HOMA-IR) was calculated with the
formula described by Matthews et al [27]: HOMA-IR =
fasting insulin (in microunits per milliliter) ⁎ fasting glucose
(in millimoles per liter)/22.5. We calculated the Framingham
risk score for CHD according to Wilson et al [28].
2.3. Anthropometric measurements
Body mass index was calculated from weight and height
measurements (in kilograms per square meter), and %BF was
estimated with a Tanita (Arlington Heights, IL) TBF-300A
bioelectrical impedance analyzer. Visceral adiposity was
estimated using waist circumference measurement [29]; and
subcutaneous fat accumulation was evaluated using the sum
of 4 skin folds: triceps, subscapular, abdominal, and thigh
[30]. Measurements of waist circumference and skin folds
were made by trained individuals and according to the
protocols described in the NHANES III Anthropometric
Procedures Manual [31].
2.4. Statistical analysis
Statistical analyses were performed with SPSS software
version 14.0 (SPSS, Chicago, IL). Descriptive statistical
analysis was conducted to determine the frequency distribu-
tion of variables, location (mean), and dispersion parameters
(standard error and range). The nonparametric 2-sided
Mann-Whitney test was applied to test differences between
Table 1
Sex differences in Yup'ik Eskimos for selected anthropometric and
metabolic characteristics
Men Women
n Mean ± SE n Mean ± SE
Age (y) 316 40 ± 0.90 353 40 ± 0.85
BMI (kg/m2)† 315 26.0 ± 0.23 351 29.3 ± 0.36
%BF† 315 21.6 ± 0.40 351 35.7 ± 0.47
Waist circumference (cm) 313 89.6 ± 0.68 351 91.9 ± 0.82
Sum of skin folds (mm)† 307 58.9 ± 1.83 346 118.2 ± 2.15
Glucose (mmol/L)⁎ 316 5.22 ± 0.03 353 5.13 ± 0.03
Insulin (μU/mL)† 314 13.1 ± 0.39 352 15.5 ± 0.48
Leptin (ng/mL)† 316 3.67 ± 0.19 352 16.5 ± 0.52
Leptin/BMI† 315 0.13 ± 0.11 351 0.53 ± 0.25
Leptin/%BF† 315 0.15 ± 0.10 351 0.44 ± 0.20
Adiponectin (μg/mL) 316 9.77 ± 0.28 353 10.4 ± 0.31
Triglycerides (mg/dL) 316 86.2 ± 3.18 351 80.6 ± 1.94
HDL-C (mg/dL)† 316 58.1 ± 0.94 351 65.3 ± 0.97
LDL-C (mg/dL) 316 143.8 ± 2.27 351 138.6 ± 1.96
HOMA-IR† 314 3.07 ± 0.10 352 3.61 ± 0.13
⁎ P ≤ .05.
† P ≤ .001.
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was less than 30.
The following transformations were used to normalize
distributions: square root of adiponectin; inverse BMI;
inverse waist circumference; and log10 of fasting plasma
glucose, plasma insulin, leptin, triglycerides, HDL-C,
LDL-C, and HOMA-IR values.
Relationships between adiponectin and metabolic and
anthropometric variables were examined using linear regres-
sion analysis. To test for significant differences between
Pearson correlation coefficients of adiponectin with cova-
riates, we tested the equality of pairs of correlations [32,33].
To compare adiponectin concentrations between groups
of individuals with higher and lower degrees of insulin
sensitivity, we defined a HOMA-IR cutoff value (ie, 3.52)
as the lower limit of the top quintile of HOMA-IR
distribution values in individuals with BMI not exceeding
25 and with no metabolic disorders [34]. In these
participants (n = 88), the limits of HOMA-IR values of
the 5 quintiles were as follows: 0.60 to 1.77, 1.78 to 2.09,
2.10 to 2.55, 2.56 to 3.51, and 3.52 to 6.36. Other studies
suggested lower HOMA-IR cutoff values: 2.77 [34], 2.68
[35], or 2.50 [36]; and we used the lowest cutoff value for
comparison of adiponectin levels in participants with higher
and lower degrees of insulin sensitivity.
Because the number of participants with CHD was only
15 in the present study, we calculated a Framingham score
for CHD [28] in all individuals and compared adiponectin
plasma concentrations in participants with low and high risk
indices of −2 vs greater than or equal to 6 (2% and ≥11%
risk for developing CHD, respectively).
To evaluate whether adiponectin concentrations in Yup'ik
Eskimos differ from those in whites, we compared
adiponectin levels from 20 male and 21 female individuals
(Yup'ik and white). All samples were measured in the same
radioimmunoassay. Men and women were pairwise matched
for age and BMI; that is, each Yup'ik individual was matched
with a white individual of similar age and BMI. Measure-
ments in white individuals were performed on plasma
samples collected at baseline from a nutritional supplements
study conducted in Dr Havel's laboratory at the University of
California, Davis (unpublished).3. Results
Anthropometric and metabolic characteristics of Yup'ik
Eskimos are presented in Table 1. On average, individuals
were 40 years old; and age did not differ by sex. Compared
with men, women had a significantly higher BMI, %BF, sum
of skin folds, insulin, HDL-C, HOMA-IR, and leptin
(absolute and adiposity corrected) values. Only glucose
levels were significantly higher in men compared with
women. Waist circumference, plasma adiponectin, triglyce-
rides, and LDL-C concentrations did not differ between men
and women.The correlations of adiponectin with selected anthropo-
metric and metabolic variables are shown separately for
men and women in Table 2. Most of the correlations were
of a similar magnitude and in the same direction for men
and women alike. For both men and women, adiponectin
had a moderate negative correlation with BMI, %BF, waist
circumference, the sum of skin folds, triglycerides, insulin,
HOMA-IR, and leptin. For both men and women,
adiponectin had moderate positive correlations with
HDL-C. The correlation of adiponectin with LDL-C was
weaker, but positive and significant for women; the same
correlation was not significant for men. Age was not
correlated with adiponectin (Table 2), although BMI, %BF,
and waist circumference increased with age (data not
shown). Linear regression analysis among selected vari-
ables indicated that the sum of skin folds and BMI had the
strongest correlation with adiponectin in men, and HDL-C
and the sum of skin folds in women (Table 2). We tested
for significant differences between the strongest correla-
tions (Pearson correlation coefficients N.2 and b−.2), and
the results are shown in Table 3. In men, only the
correlation coefficient of adiponectin and the sum of skin
folds differed from the correlation coefficients of adipo-
nectin and other variables (BMI, %BF, insulin, HOMA-IR,
triglycerides, and leptin). Thus, adiponectin had the
strongest correlation with the sum of skin folds in men
(Table 2). In women, the correlation between adiponectin
and HDL-C was not different from those observed for the
waist circumference, %BF, the sum of skin folds, insulin,
HOMA-IR, triglycerides, or leptin (Table 3). Only 2
correlations were significantly different from the others:
the correlations of adiponectin with the waist circumference
and with the sum of skin folds were significantly stronger
than the correlation of adiponectin and BMI (Table 2).
Thus, for women, when compared with the waist
Table 2
Pearson correlation coefficients by sex of plasma adiponectina with selected
anthropometric and metabolic variables
Variable Transformation Men Women
BMI −(Inverse) −0.344† −0.306†
%BF – −0.297† −0.337†
Waist circumference −(Inverse) −0.341† −0.367†
Sum of skin folds – −0.412† −0.369†
HDL-C Log10 0.343† 0.400†
LDL-C Log10 −0.076 0.092⁎
Triglycerides Log10 −0.245† −0.335†
Insulin Log10 −0.237† −0.316†
Glucose Log10 −0.031 −0.189†
HOMA-IR Log10 −0.228† −0.325†
Leptin Log10 −0.307† −0.333†
Age – 0.040 0.074
a Square-root transformed.
⁎ P ≤ .05.
† P ≤ .001.
Table 3
Differences in Z scores by sex for 2 correlations: adiponectin with correlate
A vs adiponectin with correlate B
Adiponectin correlated with Difference in Z scores
Correlate A Correlate B Men Women
HDL-C Waist circumference 0.030 0.557
HDL-C BMI −0.015 1.533
HDL-C %BF 0.647 1.027
HDL-C Sum of skin folds −1.117 0.533
HDL-C Insulin 1.522 1.394
HDL-C HOMA-IR 1.622 1.715
HDL-C Triglycerides 1.553 1.123
HDL-C Leptin 0.514 1.119
Waist circumference BMI −0.142 2.998⁎
Waist circumference %BF 1.873 1.729
Waist circumference Sum of skin folds −1.894 −0.076
Waist circumference Insulin 1.608 1.021
Waist circumference HOMA-IR 1.801 1.463
Waist circumference Triglycerides 1.543 0.608
Waist circumference Leptin 0.918 0.980
BMI %BF 1.922 −1.813
BMI Sum of skin folds −1.977⁎ −2.671‡
BMI Insulin 1.651 −0.196
BMI HOMA-IR 1.812 −0.383
BMI Triglycerides 1.608 −0.521
BMI Leptin 0.946 −0.858
%BF Sum of skin folds 3.113‡ 1.314
%BF Insulin −0.920 −0.407
%BF HOMA-IR −1.089 −0.240
%BF Triglycerides −0.814 −0.036
%BF Leptin 0.285 −0.126
Sum of skin folds Insulin 2.793‡ 1.049
Sum of skin folds HOMA-IR 2.910‡ 0.894
Sum of skin folds Triglycerides 2.760‡ 0.622
Sum of skin folds Leptin 2.945‡ 1.191
Insulin Homa-IR 0.709 −0.984
Insulin Triglycerides −0.124 −0.338
Insulin Leptin −1.145 −0.339
HOMA-IR Triglycerides −0.264 −0.181
HOMA-IR Leptin −1.318 −0.162
Triglycerides Leptin −1.016 0.037
⁎ P ≤ .05.
‡ P ≤ .01.
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significantly weaker correlation with adiponectin.
We found a weak but significant negative association
between adiponectin and fasting plasma glucose levels in
women (Table 2). Plasma adiponectin levels tend to differ in
women with NFG and IFG: 10.68 ± 0.36 μg/mL (n = 285) vs
9.23 ± 0.62 μg/mL (n = 67), P = .052. Plasma adiponectin
concentrations did not differ in men with NFG (9.67 ±
0.33 μg/mL, n = 239) and IFG (10.11 ± 0.53 μg/mL, n = 73),
P = .334. Because the number of individuals with diabetic
values of fasting glucose was small (1 woman and 4 men), we
did not include them in the analysis.
We found that insulin-sensitive individuals (HOMA-IR
b3.52, n = 442) had higher plasma adiponectin concentrations
than the insulin-resistant individuals (HOMA-IR ≥3.52, n =
224): 11.02 ± 0.27 μg/mL vs 8.26 ± 0.32 μg/mL, P b .001.
The difference remained significant when we used HOMA-IR
values of less than 2.50 (11.41 ± 0.36 μg/mL, n = 255) vs
greater than or equal to 2.50 (9.27 ± 0.25 μg/mL, n = 411),
P b .001 [36].
Plasma adiponectin concentrations did not differ between
groups of individuals with a Framingham score of −2 for
CHD (9.60 ± 0.34 μg/mL, n = 223) vs greater than or equal
to 6 (9.94 ± 0.54 μg/mL, n = 94), P = .831. Plasma
adiponectin levels were slightly higher in Yup'ik Eskimos
compared with age- and BMI-matched whites, but the
differences were not statistically significant for men (P = .94)
or for women (P = .74) as shown in Table 4.Table 4
Adiponectin concentrations (in micrograms per milliliter) in Alaskan Yup'ik
Eskimos and whites matched for age and BMI
Yup'ik White
n Mean ± SD n Mean ± SD
Men 20 8.15 ± 3.26 20 8.09 ± 2.60
Women 21 10.11 ± 5.22 21 9.62 ± 4.314. Discussion
4.1. Adiponectin and adiposity
In the present population-based study of Yup'ik Eskimos,
we found that adiponectin was inversely correlated with
adiposity assessed by either BMI or %BF, consistent with
previously reported results [16,21,22,37-41]. Our results
showed significant inverse correlations between waist cir-cumference and adiponectin levels that are consistent with
recent studies reporting that the amount of intraabdominal fat
modulates circulating adiponectin levels [13-15].
Central obesity and intraabdominal fat accumulation have
been shown to be more strongly associated with decreased
adiponectin levels than subcutaneous fat [13,16]. In our
Yup'ik study population, waist circumference, a measure of
central adiposity, did not differ between women and men,
26 A.V. Goropashnaya et al. / Metabolism Clinical and Experimental 58 (2009) 22–29although BMI and %BF were higher among women. This
result might be due to a greater accumulation of subcuta-
neous fat among women. This is supported by our
observation that the sum of skin fold thicknesses in Yup'ik
women was twice as high as that in Yup'ik men, and this
difference in subcutaneous adipose deposition does not
appear to influence circulating adiponectin concentrations
because we found no difference between men and women.
Several other obesity studies on the Inuit have used waist
circumference as a proxy for visceral fat and obtained similar
results to those reported in this study [42-44]. However, wide
variations in fat distribution exist among different ethnic
groups using waist circumference as a proxy for visceral fat
[30,45-47]. In the meantime, the observed associations
between waist circumference and visceral fat should be
viewed with caution.
Although we did not measure adipocyte size in this
study, we hypothesize that adipocyte hypertrophy leads to
decreased circulating adiponectin concentrations because
large, insulin-resistant adipocytes with greater triglyceride
stores secrete less adiponectin than smaller, insulin-
sensitive adipocytes [3].
We had a wide age range of 18 to 94 years among our
participants, with the average age for both men and women
being 40 years. Despite predictions that plasma adiponectin
levels decrease with age because of an increase in BMI, %
BF, and visceral adiposity accumulation, we did not find a
significant association between adiponectin concentrations
and age, although BMI, %BF, and waist circumference in all
participants were positively associated with age. Contrary to
our observations, Cnop et al [16] showed that plasma
adiponectin levels were modestly but significantly positively
associated with age.
4.2. Adiponectin and insulin resistance
Japanese, Pima Indians, and whites with diabetes have
lower plasma adiponectin levels than nondiabetic individuals
of the same ethnicity [17,21]; however, Looker et al [18]
showed that adiponectin levels increased with the duration of
type 2 diabetes mellitus in Pima Indians. Although an oral
glucose tolerance test was not conducted in the present study,
we did assess fasting plasma glucose and plasma insulin levels
and evaluated insulin resistance by calculating HOMA-IR
levels. Homeostasis model assessment of insulin resistance is
less accurate than the glucose clamp or the oral glucose
tolerance test; however, this limitation is mitigated when a
large number of participants are examined as in the present
study [34]. Yup'ik Eskimos with elevated HOMA-IR values
had lower adiponectin concentrations than individuals with
low HOMA-IR values. Interestingly, plasma adiponectin
levels did not differ in participants with NFG and IFG,
suggesting that adiponectin concentrations are more closely
associated with insulin resistance than with moderately
elevated plasma glucose levels. This result is consistent with
the results of Hotta et al [48] who observed that plasmaadiponectin levels begin to decline at an early stage of obesity
in rhesus monkeys in parallel with the decrease in insulin
sensitivity and before the appearance of frank hyperglycemia.
Our results demonstrated that adiponectin concentrations
were inversely correlated with triglycerides, insulin, and
insulin resistance, consistent with results from other studies
in various populations [16,21,22,39,40]. Based on the
known actions of adiponectin, it seems biologically plausible
that circulating adiponectin concentrations are determinants
of insulin sensitivity [3] rather than insulin sensitivity
affecting adiponectin production. This would be similar to
the relationship between circulating adiponectin and HDL-C
concentrations as proposed by Cnop et al [16] in which
adiponectin was hypothesized to increase HDL-C production
rather than the converse. Nonetheless, the metabolic
sequelae leading to insulin resistance and type 2 diabetes
mellitus need to be definitively determined in interventional
mechanistic study designs.
Individuals with low plasma adiponectin concentrations
at baseline are more likely to develop type 2 diabetes
mellitus than those with high concentrations [12,49-51].
This was shown in individuals with both normal and
impaired glucose tolerance at baseline. Observations of this
nature can only be made in studies where participants are
repeatedly measured over time. Longitudinal measurements
in the participants of the present study over the next several
years may reveal whether low adiponectin levels are
predictive of the development of type 2 diabetes mellitus
in Yup'ik Eskimos.
4.3. Adiponectin and CHD
Increased plasma lipid concentrations are associated with
the elevated risk and incidence of cardiovascular disease
[52]. Adiponectin is positively correlated with HDL-C and
acts as an endogenous antiatherogenic factor [3,39,53-55].
We found a positive association between adiponectin and
HDL-C in our Yup'ik study population; however, in a
comparison of individuals with low risk vs high risk for
CHD, based on their Framingham score, plasma adiponectin
levels did not differ.
Adiponectin circulates in human plasma mainly as high–
molecular weight (HMW) and low–molecular weight
multimers [56]. Lara-Castro et al [57] reported that the
HMW form, not total or HMW-to-total ratio, was primarily
responsible for the observed relationships between adipo-
nectin and metabolic syndrome traits (insulin sensitivity and
abdominal fat but not total fat mass and BMI). Bobbert et al
[58] showed that the HMW form of adiponectin was more
closely correlated with HDL-C than total adiponectin. We
did not measure the HMW form of adiponectin because there
was no high throughput assay available at the time we
initiated this study. Therefore, it is also possible that sex
differences in the associations of adiponectin and different
metabolic traits might be better explained with data on HMW
multimeric values.
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concentrations than men in our study sample, and these
differences remained when BMI and %BF were controlled.
Our observations are similar to those reported by Havel et al
[59]: plasma leptin was 4 times higher in normal-weight
women than in men independent of age, reproductive status,
and hormone replacement. Cnop et al [60] also found that
leptin concentrations were 3-fold higher in obese women
than in obese men, whereas the sex differences were 2-fold in
lean individuals. As a whole, this group of studies suggests
that women, regardless of the presence of obesity and insulin
resistance, have much higher leptin values compared with
men; but the explanation for this is not known.
4.4. Ethnic differences in adiponectin levels
Findings to date do not present a coherent picture of the
relationship of adiponectin and ethnicity. Weyer et al [21]
found that plasma adiponectin levels were lower in Pima
Indians than in whites adjusted for age, sex, and %BF and
that adiponectin was associated with insulin sensitivity
irrespective of ethnic origin. Hulver et al [20] showed that
plasma adiponectin concentrations did not differ among
obese white, and obese and nonobese African American
women. They also demonstrated that BMI, insulin, and
HOMA-IR did not correlate with adiponectin among African
Americans. These striking findings of the lack of association
could be a result of ethnic differences. Kadowaki et al [61]
reported higher levels of adiponectin in American men
compared with Japanese men in all waist circumference
tertile groups. Kanaya et al [23] found that older white
Americans had higher circulating adiponectin concentrations
compared with older blacks, although adiponectin levels
were lower among whites with CHD than among whites
without CHD. Although we used a small sample of age- and
BMI-matched whites as a comparison group, we did not find
significant differences in plasma adiponectin levels among
Yup'ik Eskimos compared with whites. Because our sample
size was small and individuals in our study were matched for
BMI and not visceral adiposity, this conclusion should be
taken with caution.
Despite significantly higher BMI and %BF in Yup'ik
women than in men, plasma adiponectin concentrations did
not differ between men and women in the Yup'ik population.
Inconsistent findings have been reported in other studies of
sex differences. In studies of Native Canadians [22],
Japanese [39], African Americans [62], and whites [16],
adiponectin levels were found to be significantly higher
among female than male subjects. However, no difference in
adiponectin concentrations between men and women has
also been reported in whites [63]. In Pima Indians, despite
differences in %BF, no difference in adiponectin levels
between men and women was found [21]. These incon-
sistencies in findings might be a result of differences in
intraabdominal fat accumulation in men and women in
different studies.In conclusion, in the present study, we observed that
adiponectin levels in Yup'ik Eskimos are inversely
correlated with waist circumference, triglycerides, insulin
concentrations, and HOMA-IR, but positively correlated
with HDL-C levels. We found that circulating adiponectin
concentrations were most strongly associated with sum of
skin folds in Yup'ik men and with HDL-C levels, sum of
skin folds, waist circumference, and insulin and triglyce-
rides concentrations in Yup'ik women. Future longitudinal
studies of Yup'ik Eskimos are needed to determine whether
decreased circulating adiponectin concentrations are pre-
dictive or an important risk factor for serious metabolic
diseases such as type 2 diabetes mellitus and CHD.
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